This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Cardinal Health (CAH) Beats on Q2 Earnings, Ups FY19 View
by Zacks Equity Research
Cardinal Health's (CAH) Q2 results benefit from strong sales in the Pharmaceutical segment. An upbeat guidance is indicative of brighter prospects.
Cardinal Health (CAH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 18.35% and 4.10%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Cardinal Health's (CAH) Q2 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) likely to gain from solid Pharmaceutical revenues in fiscal Q2; medical-gloves sub-segment likely to be soft.
Cardinal Health (CAH) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Molecular Diagnostics Drive Myriad's (MYGN) Q2 Earnings?
by Zacks Equity Research
Myriad (MYGN) likely to deliver solid Q2 results on the diversified Molecular Diagnostics portfolio with products like GeneSight, EndoPredict, BRACAnalysis CDx and Prolaris tests.
Cigna (CI) Poised to Beat Q4 Earnings on Revenue Growth
by Zacks Equity Research
Cigna's (CI) Q4 results are likely to gain from increase in revenues and membership.
Zacks.com featured expert Kevin Matras highlights: American Airlines, ArcBest, AmerisourceBergen, Cardinal Health and CVS Health
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: American Airlines, ArcBest, AmerisourceBergen, Cardinal Health and CVS Health
5 Stocks in Focus After Recent Broker Rating Upgrades
by Zacks Equity Research
The guidance to design a winning portfolio comes from brokers given their thorough understanding of the stock market.
Zacks.com featured highlights include: ArcBest, American Airlines, Cardinal, Century Aluminum and CVS
by Zacks Equity Research
Zacks.com featured highlights include: ArcBest, American Airlines, Cardinal, Century Aluminum and CVS
5 Broker Favorite Stocks to Watch Out For
by Zacks Equity Research
The task of designing one's portfolio to include potential outperformers is not an easy one. Broker advice is necessary to design a winning portfolio.
Should Value Investors Pick Cardinal Health (CAH) Stock Now?
by Zacks Equity Research
Let's see if Cardinal Health, Inc. (CAH) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Cardinal (CAH) Down 4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Cardinal Health (CAH) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Cardinal Health (CAH) stock is a good choice for value-oriented investors right now from multiple angles.
Cardinal Health to Highlight Cost-Control Approach in ASHP
by Zacks Equity Research
Cardinal Health (CAH) helps hospitals identify hidden savings, improve patient outcomes and drive supply chain efficiencies.
Company News For Nov 8, 2018
by Zacks Equity Research
Companies In The News Are: CAH,DHI,TRIP,WYNN
Cardinal Health (CAH) Surpasses Earnings Estimates in Q1
by Nabaparna Bhattacharya
Cardinal Health (CAH) Q1 results benefit from strong sales in the Pharmaceutical and the Medical segments.
Cardinal Health (CAH) Beats on Earnings & Revenues in Q1
by Zacks Equity Research
Cardinal Health's (CAH) solid segmental performance buoys optimism. FY19 view reiterated.
Earnings Preview: Cardinal Health (CAH) Q1 Earnings Expected to Decline
by Zacks Equity Research
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Cardinal Health's (CAH) Q1 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) likely to gain from solid Pharmaceutical revenues in fiscal Q1; medical-gloves sub-segment likely to be soft.
New Strong Sell Stocks for October 17th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Why Is Cardinal (CAH) Up 0.9% Since Last Earnings Report?
by Zacks Equity Research
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cardinal Health Product Spectrum Broad, Competition Rife
by Zacks Equity Research
Cardinal Health's (CAH) strategic buyouts lend it a competitive edge; the Cordis unit lacks luster.
Cardinal Health (CAH) Surpasses Earnings Estimates in Q4
by Zacks Equity Research
Cardinal Health (CAH) witnesses strong Q4, owing to strong sales at Pharmaceutical and the Medical segments. It provides an impressive FY19 view.
Cardinal Health (CAH) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 8.60% and 2.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Stock Earnings on Aug 6: CAH, HSIC & More
by Zacks Equity Research
The Medical product market gains momentum owing to the recent two-year suspension of the controversial 2.3% Medical Device tax.